Physician profile
Robert L Lindenberg
NPI 1770576936
$1,548.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $121 · 2021: $99.01 · 2022: $712.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $222.43 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $181.77 | 2019-2022 | |
| Janssen Biotech, INC. | $148.42 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.66 | 2019 | |
| Allergan, INC. | $122.53 | 2019-2020 | |
| Celgene Corporation | $75.01 | 2022 | |
| Covidien LP | $39.08 | 2019-2020 | |
| Gilead Sciences, INC. | $37.52 | 2019 | |
| Merck Sharp & Dohme LLC | $37.46 | 2019-2020 | |
| Genzyme Corporation | $32.70 | 2022 | |
| Ferring Pharmaceuticals INC. | $31.66 | 2022 | |
| Ucb, INC. | $30.92 | 2019 | |
| Braintree Laboratories, INC. | $21.90 | 2022 | |
| Amgen INC. | $20.28 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $19.73 | 2022 | |
| Alfasigma USA, INC. | $14.35 | 2020 | |
| Intercept Pharmaceuticals, INC. | $13.39 | 2022 | |
| Ironwood Pharmaceuticals, INC | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lindenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.